Iovance Biotherapeutics (NASDAQ:IOVA) raised its full-year 2026 total revenue guidance to between $410 million and $420 million, compared with its previous forecast of $350 million to $370 million.
The midpoint of the revised range is $55 million above the midpoint of the previous guidance and represents an increase of approximately 15%.
Iovance said the new forecast implies total revenue growth of nearly 60% for 2026, with the revision attributed to US demand for Amtagvi (lifileucel) and Proleukin.
Second-Quarter Product Revenue Reaches $99.3 Million
Iovance reported total product revenue of $99.3 million for the second quarter of 2026, which the company described as a quarterly record.
The company said demand for Amtagvi and Proleukin, together with its current manufacturing schedule, contributed to its decision to increase the full-year forecast.
“Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint. Increasing patient demand and our current manufacturing schedule provide strong visibility into our third and fourth quarter revenues,” said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer.
The comments regarding visibility into future revenue represent management’s expectations and remain subject to the company’s commercial and manufacturing performance.
Treatment Centre Network Approaches 100 Locations
Iovance said its network of authorised treatment centres has expanded to approximately 100 locations.
The company continues to target at least 110 authorised treatment centres by the end of 2026.
Expansion of the treatment centre network forms part of Iovance’s commercial infrastructure for providing access to its therapies.
Third-Quarter Results Expected in November
Iovance expects to report its third-quarter 2026 financial results in early November.
The revised $410 million to $420 million full-year revenue range remains company guidance and is subject to factors including patient demand, treatment volumes and manufacturing execution during the remainder of the year.
Iovance Biotherapeutics stock price
